Edwards Lifesciences Corp (NYSE:EW) Director William J. Phd Link sold 13,578 shares of the stock in a transaction dated Monday, November 19th. The shares were sold at an average price of $149.92, for a total value of $2,035,613.76. Following the completion of the sale, the director now owns 16,730 shares of the company’s stock, valued at approximately $2,508,161.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

NYSE:EW opened at $149.59 on Wednesday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.85 and a current ratio of 2.31. Edwards Lifesciences Corp has a 52 week low of $107.49 and a 52 week high of $175.00. The company has a market cap of $31.33 billion, a price-to-earnings ratio of 39.37, a PEG ratio of 1.97 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, October 23rd. The medical research company reported $1.07 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.05. Edwards Lifesciences had a return on equity of 30.11% and a net margin of 20.67%. The company had revenue of $906.60 million for the quarter, compared to the consensus estimate of $927.56 million. During the same quarter last year, the business posted $0.84 EPS. Edwards Lifesciences’s quarterly revenue was up 10.4% compared to the same quarter last year. On average, research analysts forecast that Edwards Lifesciences Corp will post 4.7 earnings per share for the current fiscal year.

A number of research firms have recently issued reports on EW. Citigroup increased their target price on Edwards Lifesciences from $115.00 to $118.00 and gave the company a “sell” rating in a research note on Tuesday, July 31st. ValuEngine raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Wednesday, September 19th. Bank of America downgraded Edwards Lifesciences from a “buy” rating to a “neutral” rating in a report on Tuesday, October 2nd. Morgan Stanley increased their price target on Edwards Lifesciences from $150.00 to $157.00 and gave the company an “overweight” rating in a report on Thursday, October 11th. Finally, SunTrust Banks reduced their price target on Edwards Lifesciences to $170.00 and set a “buy” rating for the company in a report on Friday, August 10th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. Edwards Lifesciences currently has an average rating of “Buy” and a consensus price target of $156.79.

Large investors have recently added to or reduced their stakes in the business. Principal Financial Group Inc. lifted its holdings in shares of Edwards Lifesciences by 5.4% in the 1st quarter. Principal Financial Group Inc. now owns 461,654 shares of the medical research company’s stock worth $64,409,000 after purchasing an additional 23,652 shares during the last quarter. Xact Kapitalforvaltning AB lifted its holdings in shares of Edwards Lifesciences by 2.6% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 42,018 shares of the medical research company’s stock worth $6,117,000 after purchasing an additional 1,084 shares during the last quarter. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Edwards Lifesciences by 461.5% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 2,409 shares of the medical research company’s stock worth $351,000 after purchasing an additional 1,980 shares during the last quarter. Cornerstone Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth approximately $678,000. Finally, Creative Planning lifted its holdings in shares of Edwards Lifesciences by 2.5% in the 2nd quarter. Creative Planning now owns 34,705 shares of the medical research company’s stock worth $5,052,000 after purchasing an additional 849 shares during the last quarter. 81.27% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Edwards Lifesciences Corp (EW) Director Sells $2,035,613.76 in Stock” was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another publication, it was stolen and republished in violation of United States and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/11/21/edwards-lifesciences-corp-ew-director-sells-2035613-76-in-stock.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.

Further Reading: Bear Market – How and Why They Occur

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.